Home > Research > Publications & Outputs > Predicted Impact of COVID-19 on Neglected Tropi...

Associated organisational unit

Links

Text available via DOI:

View graph of relations

Predicted Impact of COVID-19 on Neglected Tropical Disease Programs and the Opportunity for Innovation

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published
  • Jaspreet Toor
  • Emily R. Adams
  • Maryam Aliee
  • Roy M. Anderson
  • Diepreye Ayabina
  • Robin Bailey
  • Maria Gloria Basáñez
  • David J. Blok
  • Seth Blumberg
  • Anna Borlase
  • Rocio Caja Rivera
  • María Soledad Castaño
  • Nakul Chitnis
  • Luc E. Coffeng
  • Ronald E. Crump
  • Aatreyee Das
  • Christopher N. Davis
  • Emma L. Davis
  • Michael S. Deiner
  • Federica Giardina
  • Matthew Graham
  • Jonathan I.D. Hamley
  • Ching I. Huang
  • Klodeta Kura
  • Thomas M. Lietman
  • Tim C.D. Lucas
  • Veronica Malizia
  • Graham F. Medley
  • Aronrag Meeyai
  • Edwin Michael
  • Travis C. Porco
  • Joaquin M. Prada
  • Kat S. Rock
  • Epke A. Le Rutte
  • Morgan E. Smith
  • Simon E.F. Spencer
  • Wilma A. Stolk
  • Panayiota Touloupou
  • Andreia Vasconcelos
  • Carolin Vegvari
  • Sake J. de Vlas
  • Martin Walker
  • T. Déirdre Hollingsworth
Close
<mark>Journal publication date</mark>15/04/2021
<mark>Journal</mark>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Issue number8
Volume72
Number of pages4
Pages (from-to)1463-1466
Publication StatusPublished
Early online date28/09/20
<mark>Original language</mark>English

Abstract

Due to the COVID-19 pandemic, many key neglected tropical disease (NTD) activities have been postponed. This hindrance comes at a time when the NTDs are progressing towards their ambitious goals for 2030. Mathematical modelling on several NTDs, namely gambiense sleeping sickness, lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiases (STH), trachoma, and visceral leishmaniasis, shows that the impact of this disruption will vary across the diseases. Programs face a risk of resurgence, which will be fastest in high-transmission areas. Furthermore, of the mass drug administration diseases, schistosomiasis, STH, and trachoma are likely to encounter faster resurgence. The case-finding diseases (gambiense sleeping sickness and visceral leishmaniasis) are likely to have fewer cases being detected but may face an increasing underlying rate of new infections. However, once programs are able to resume, there are ways to mitigate the impact and accelerate progress towards the 2030 goals.